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Summary.-The radiosensitizing efficiencies of 4 structural analogues of misonida-
zole (MISO) have been compared with that of the parent compound. Three of these
were charged basic compounds, previously shown in vitro to be 10 times more
efficient. Enhancement ratios were measured from pairs of tumour growth-delay
curves for the mouse fibrosarcoma SA Fab. Two routes of administration and ranges
of drug dose and intervals between injection and irradiation were tested.
Drug concentrations in blood, brain and tumour were measured using high-
performance liquid chromatography. The peak concentration in tumours coincided
with the peak in radiosensitization: 20 min after i.v. injection and 40 min after i.p.
injection. The concentration in tumours was similar for either route.
Comparison of radiosensitizing efficiency on the basis of equal administered dose
showed no difference between the 5 compounds, but after equimolar doses the
charged compounds achieved lower tumour concentrations. Comparison of sensitiz-
ing efficiency on the basis of tumour concentration showed that they were 3 times
more potent than MISO, as predicted from their higher electron-affinity. The result-
ant improvement in radiosensitization at low, clinically relevant, concentrations is
so slight that any therapeutic benefit would depend on reduced drug toxicity in man.
THE RADIATION RESPONSE of experi-
mental tumours is profoundly influenced
by the presence of naturally occurring
hypoxic cells which are radio-resistant and
whichdominate tumourresponse afterhigh
single doses of X-rays (Thomlinson &
Craddock, 1967). Chemical radiosensitizers
have been developed which mimic 02 as a
sensitizer, and should diffuse through the
tumour to the critical hypoxic cells
(Adams et al., 1976). Two of these, the 2-
nitroimidazole, misonidazole (MISO), and
the 5-nitroimidazole, metronidazole, have
been shown to sensitize most animal
tumours (for reviews see Denekamp et al.,
1980a; Fowler & Denekamp, 1979) and are
currently being tested in clinical trials
throughout the world. Large drug doses
are needed to achieve radiosensitization
and the clinical success of these drugs is
limited by their neurotoxicity and gastro-
9
intestinal side effects (Coleman et al., 1982;
Dische et al., 1979, 1981, 1982; Urtasun et
al., 1975, 1978; Wasserman et al., 1979).
A more effective or less toxic radio-
sensitizer is therefore needed for use in the
clinic. In vitro studies have indicated that
a group of 2-nitroimidazoles with basic
properties is 10 times more efficient irt
vitro than MISO or its metabolite des-
methylmisonidazole (Ro 05-9963) (Fig. 1,
Table I), though only a 3-fold increase was
expected on the basis of electron-affinity
(Smithen et al., 1980). It was hoped that
their basicity would lead to more rapid
excretion in an acid urine, thus reducing
tissue exposure and toxic side-effects. If
the increased efficiency persisted in vivo, or
if there were reduced toxicity, these
compounds would clearly be potential
successors to MISO for clinical use.
We have tested 3 of these charged basic128 M. V. WILLIAMS, J. DENEKAMP, A. I. MINCHINTON AND M. R. L. STRATFORD
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30 ditions were used. When tumours were
* j implanted on the back, 6 mice were irradiated S / simultaneously, without anaesthetic, at a
2-5-/ / dose rate of 3-2 Gy/min (for details see
4. n X / *Sheldon & Hill, 1977). Mice whose tumours
v.,I had been implanted on the chest were 20 / ,. anaesthetized with sodium pentobarbitone
50I 0/1J
/ o,°" (60 mg/kg) 10 min before irradiation, and 4
15 */+
o
mice were then irradiated simultaneously at a , ,o,0E4 '
1 dose rate of2-2 Gy/min (for details see Fowler
et al., 1975). In all experiments dose
10 -~> -2 - | uniformity was ensured by turning the mice
and delivering half the radiation dose from Drug concentration (log M) each side.
FIG. 1. In vitro results (Smithen et al., 1980; The radiosensitizing compounds were dis-
M. E. Watts, unpublished): SER' in- solved in sterile saline shortly before use.
creases with drug concentration. MISO They were protected from light and warmed (0) and 9963 (0) fall on a common line,
as do the 3 basic compounds: 8799 (A), to 37WC before injection. Drug dose was
0052 (M) and 0054 (y). There is a 10-fold adjusted according to body weight for each
difference in radio-sensitizing efficiency. mouse. The maximum volume injected was
1 0 ml i.p. or 0 4 ml i.v. The i.v. injections
mpounds in a series of experiments, were given slowly (45 sec) to avoid vascular
gether with MISO and Ro 05-9963. The shock. A range of drug doses was used, and
mpounds have been compared on the the interval between injection and irradiation
lsis of administered dose and of tumour was varied in some experiments.
ncentrations measured by high-perform- The timing of radiosensitizer injections is
tce liquid chromatography. quoted relative to the mid-point of irradia- tion, so that the interval between injection
and the start of irradiation varied by about MATERIALS AND METHODS 5 min for the different radiation dose groups.
Tumour growth delay was used to measure After irradiation, tumours were measured
e radiosensitizing efficiency of the 5 com- as before and growth delay was estimated
ounds. The tumour was a spontaneous from the time taken for each individual
)rosarcoma (SA FAb) which has been tumour to increase its size by a fixed
aintained by serial transplantation in the increment, which in different experiments was
rain of origin (WHT/GyfBSVS). The tum- either 3-5 or 4-5 mm GMD, corresponding to a
ir has a volume-doubling time of4 days and 4-5-fold increase in volume. The mean delay
estimated hypoxic fraction of 20-50% for a dose group of 7-9 mice was then
lenekamp et al., 1980a). calculated.
Tumour transplantation was performed on The pharmacology of the compounds was
,tches of 100-150 female WHT mice, aged studied using mice of the same age, weight,
-12 weeks. Under penthrane anaesthesia, sex and strain, bearing tumours 6-7 mm in
mour fragments (0.5 mm diameter) were diameter. Mice were killed by decapitation
planted s.c. on the chest or back using a and blood samples were collected from the
)car. neck into heparinized tubes. The brain was
When the tumours became palpable they removed and the tumourdissected free ofskin
re measured with vernier calipers 3 times a and s.c. connective tissue. The tissue samples
ek in 3 orthogonal diameters. When the were placed on ice and kept at4C throughout
ometric-mean diameter (GMD) reached subsequent processing. The tissues were
7 mm the mice were randomly allocated to weighed and homogenized in 4-9 vols of
ferent treatment groups. The latent period distilled water. A suitable aliquot of these and
us 18-28 days and at the time ofirradiation of blood was taken and vortex mixed with an
e mice weighed 26-31 g. internal standard (10 ,ug Ro 07-0913). Meth-
Irradiations were performed using 240kV anol (1-2 ml) was added to precipitate protein
-rays filtered with 1 0 mm Al and 0-25 mm and the sample was mixed, centrifuged, an(d
(HVL 1-3 mm Cu). Two irradiation con- the supernatant analysed by high-perform-
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TABLE II.-HPLC Conditions a) Pharmn*tgy
Compouncl Eluent
Ro 07-0582 25% AMethanol/water
Ro 05-9963 25% Methanol/water
Ro 0:l3-8799 25% _Methanol/5mmi heptane
sulphonic acid/0 4u% ammoniuim
phosphate (pH 6 0)
Ro 31-0052 300o Methanol/5mM heptane
suiphonic acid/0 2M
ammonium phiosplhate (pH 4(0)
Ro 31-0054 25% Alethanol/0 4M ammonitim
phosphate (pH 4.0)
Flow i-ate: 2 ml/min
Column: Hypersil 5 ODS
Detectoi: Cecil Ce 2112 monitoring at 326 nrn.
s0
100 X-Rays alone
041
40- 25 j
30 -~ ~ *0
20-
10
0 10 20 30 40 50
Dow (Gy)
FIG. 2.-Growth-delay curves for SA FAb
tumours irradiated 20 min after the in(iica-
tedldoses (ytmol/g) of desmetlhylmisoni(la-
zole. With increasing drug close the sensi-
tivity of tlhe tumours increases, resulting
in higher values of SER'.
ance liquid chromatography (HPLC). For the
lower drug doses, the sample was concen-
trated by evaporating off the solvent under
N2 at 45°C. The HPLC conditions for the
different drugs are shown in Table II.
RESULTS
Fig. 2 shows representative dose-
response curves obtained using 7-9 mice
per point. In this and all subsequent
3-0 -50
7
304
19 -} ~~~~30P
20 . b X~~~~0 X , s,oW
L799- g"< 30 1-Anf 0, - 34 , 0. ...
12s°° SO
00024
- ' O 1 20 3@ 40 506.10 X D30
Time ater hnjection(in)
FIc. 3.--Time-course stuclies following ix-.
injection of 4 radiosensitizers at giveIn
closes. (a) M\easure(d tumour concentration
increases Mwith time and reaches a broad
peak between 1O and 30 mii. (b) Grow tli
(lelay after an X-ray dose of 21-7 Gy; for
all 4 compounds a 20min interval gives
optimum racliosensitization.
diagrams the error bars represent + s.e.;
where none are shown they are smaller
than the symbol. In this example des-
methylmisonidazole (Ro 05-9963), was
injected i.v. 20 min before irradiation. The
curve for tumours irradiated without drug
is biphasic. Sensitized tumours show a
more uniform increase in growth delay,
and therefore a progressive separation of
the curves leading to an increase in the
SER'.*
The precision of the SER' depends on
the precision of the estimates of X-ray
doses to produce the same growth delay.
Vertical growth-delay errors can be inter-
preted in terms of horizontal dose errors
by drawing envelopes through the error
bars. The standard error of the mean (s.e.)
for the SER' has been obtained from the
fractional errors of the standard errors of
the 2 doses. In these experiments the SER'
*SER- doseX-raysalone rto aeliieve the samelevelofra(latio)n R- lose X-rays withsensitizer effect in fully hypoxic cells.
SER'= observe(d SER for a mixe(d population of oxic an(d hypoxic cells.
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estimates had a calculated standard error
of 10%
Fig. 3 compares the measured tumour
concentrations and the radiation response
after i.v. injection of 4 of the compounds.
Three ofthe drugs were administered at an
equimolar dose of 2-5 ,umol/g. Ro 03-8799
was administered at the maximum tolera-
ted dose of 1P7 ,tmol/g. Ro 31-0054 is not
shown because it was too toxic to test at
comparable doses (i.v. LD50= 0 7 ,umol/g).
Fig. 3(a) shows the time course of drug
concentrations in tumours, measured by
HPLC. For all 4 drugs there is a plateau at
10-30 min; a similar broad peak at
5-20 min has been found after lower doses
(0 5 ,umol/g) of 4 of these compounds
(excluding Ro 05-9963) (Stratford et al.,
1982).
Fig. 3(b) shows the corresponding radio-
biological effect expressed as tumour
growth delay for mice irradiated with
21*7 Gy at various intervals after i.v.
administration of the drug. Zero time re-
presents no drug administered. Increasing
growth delay indicates radiosensitization.
The maximum delaywas seenat 10-20 min
for all 4 compounds. Based on this
assessment after high doses, a 20 min
interval was used when comparing radio-
sensitizing activity over a range of drug
doses.
MISO and Ro 03-8799 were also admin-
istered by the i.p. route for comparison
with i.v. admninistration. Time-course
studies were not performed in this work,
but previous experiments have established
that a 40 min interval between i.p. injec-
tion and the midpoint of irradiatioin
achieves optimum radiosensitization in this
tumour (Denekamp, 1982).
Fig. 4 shows the pharmacokinetics of
the 4 compounds (i.e. excluding the toxic
Ro 31-0054) in blood, brain and tumour.
The longest half-life in blood was seen for
MISO (57 min), vhich was distributed
fairly uniformly throughout the body; by
20 min the tumour and brain concentra-
tions were similar to those in blood.
Tumour levels at 20 min were higher than
those in blood for the basic compounds. Ro
'9963 2 5
i8799 17
lo~ - t
05/
o~~~~~~~~~-' 0 0 o 00 10 2 30 40 50 60
40 - 0052 25-
30
20 0
I0
10 *
0 10 20 30 40 50 6V
Time (min)
Fic,e. 4. Senisitizer coneentrationis Ineasure(t
by HPLC' afterI i.v. injectioni of the indica-
te(l (loses (rmol/g). The highest levels are
obtaine(d wvith 1ISt). Braini levels lremain
low wsitl 9963 a(llc 0052, btit 8799 concen-
trates in braini and tumour. Half-lives are
liste(l in Table ITI. = bloo(l; = tumour;
A =brainl.
03-8799 was concentrated in brain, where-
as Ro 05-9963 and Ro 31-0052 were
excluded.
Table III summarizes the pharmaco-
logical and toxicity data. After i.v.
administration the distribution phase is
rapid, and the effective distribution vol-
ume has been calculated, assuming a l-
compartment model, by extrapolating the
blood concentration curve back to zero
time. Table III indicates effective volumes
of distribution for MISO and Ro 05-9963
that are slightly less than the volume of
the mouse, whereas with Ro 03-8799 and
especially with Ro 31-0054 the effective
volumes of distribution exceed that of the
mice. This indicates rapid removal of the
compoundfromthebloodintoothertissues.
The blood, tumour and brain levels
20 min afer a smaller dose of drug
(0 5 pmol/g) are shown in Table III. The
tumour concentrations of MISO and
Ro 05-9963 are higher than those of the 3
charged compounds. The concentration in
brain is highest for MISO and Ro 03-8799.
Table III also shows tumour:brain ratios:
this value (or alternatively the area under
the concentration-time curve for brain)
could indicate the therapeutic potential of
the compound, ifthe limiting toxicity were
only CNS damage. The tumour:brain ratio
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is inversely proportional to the distribu-
tion coefficient, as might be expected for
brain exclusion ofliphophobic compounds.
The tumour:blood ratio of the basic
compounds is higher than that for MISO
and Ro 03-9963, and correlates with pKa.
However, concentrations of Ro 03-8799
werealsoraised tothe same degree in brain
(Table III), fat, skeletal muscle, and liver
(datanotshown). Thephenomenonisthere-
foreoneofconcentrationinalltissuesrather
than ofselective uptake into tumours.
Toxicity was assessed by acute lethality
(Table III). The mice were observed for 7
days, but death usually occurred within 2
days of i.p. administration, following a
period of hypothermia. Because of the
limitation placed on administered dose by
restricting the injection volume to 0 4 ml,
only a lower limit could be established for
the i.v. LD50 of MISO and Ro 05-9963.
After i.v. administration of high doses of
the basic compounds, those mice that died
did so within minutes, after severe convul-
sions. Ro 05-9963 was the least toxic
A~~~
I .. 4)" ,S
FiG '5.. iE.'.m.easue by tumour.... ..growtli. . |......
of sensitizerL.; The soli lin draw th'rou'fgh
than MIS. A,r i.p ^ , * .iv^.
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FIGl. 5. SER' measured by tumour growth
delay as a function of the administered dose
of sensitizer. The solid line drawn through
the MISO results is reproduced as a broken
line in other panels for comparison. None
of the compounds is significantly better
than MISO. A, i.p.; *, iv.
compound by either route of administra-
tion; Ro 31-0052 was similar in toxicity to
MISO, whereas Ro 03-8799 was twice as
toxic as MISO. There was no obvious
correlation between toxicity and brain
exposure or blood half-life, but Ro 31-0054
was the most toxic compound (10 times
more than MISO) and it showed a similar
increase in distribution volume; this may
indicate rapid uptake into critical tissues.
Fig. 5 compares the radiosensitizing
efficiency of the 5 compounds on the basis
of equimolar doses. The line drawn by eye
through the fibrosarcoma results for MISO
in the first panel is reproduced as a
standard for comparison on each subse-
quent graph. There is no significant differ-
ence between the results. Since the 3 basic
compounds are ofhigher molecular weight
than MISO, up to twice as much drug by
weight is needed to give the same
equimolar dose, and hence the same degree
of radiosensitization. J.v. and i.p. admin-
20/ /
oa i
O .. .. ~~ ~ ~ ~~~~~~~~~~~~~~~~~. . ........
2,r- S. -; X ,_
S /. /
c
a ,5 /olv
Sm. tizr cor t*ntrb in: tumSe (AiMwf)
Fia. 6.- SER' for tumour growth delay as a
function of measured gross tumour con-
centrations. The dashed lines represent the
in vitro data from Fig. 1 for comparison.
MISO and Ro 05-9963 appear marginally
more effective than in vitro. The three
basic compounds are significantly less
effective than in vitro, especially at low
concentrations. A, i.p.; 0. i.v.
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istration of MISO and Ro 03-8799 gave
similar results.
Radiosensitizing efficiency as a function
of measured tumour concentration is
shown in Fig. 6 and has been directly
compared with the in vitro data from Fig.
1 (dashed lines). The in vivo points are
fitted with a solid line. Slightly more
sensitization of tumours was seen with
MISO and Ro 05-9963 than would have
been predicted from the in vitro results.
The 3 basic compounds gave tumour
sensitization intermediate between the 2 in
vitro lines, showing greater efficiency than
MISO, but less than that seen with V79
cells in culture. At high concentrations, Ro
03-8799 and Ro 31-0052 were up to 4 times
more potent than MISO, but at the
lowerconcentrations, i.e. 0-01-0 12,umol/g,
(which can be achieved clinically with
10-30 fractions of MISO) there was no
significant difference between the 5 com-
pounds.
DISCUSSION
A radiosensitizer might be a clinical
successor to misonidazole if it were
either more potent or less toxic. The
present studies were designed to compare,
in concurrent experiments, the radiosensi-
tizing efficiencies of 4 analogues of
misonidazole with that of the parent
compound. A wide range ofdrug doses was
covered, from that which can be achieved
clinically with MISO, to a dose approach-
ing the toxic limit in mice. The optimum
time for irradiation was determined for
each compound at a single high dose level
(1.7-2*5 ,tmol/g) as it can vary with the
compound, the route of administration
and type of tumour (McNally et al., 1978;
Brown & Yu, 1980). The sensitization
obtained for each schedule was measured
by comparing tumour responses at high
levels of delay (> 25 days in Fig. 2);
naturally hypoxic cells then dominate the
response, and the estimate ofSER' closely
approaches the SER for a clamped, fully
hypoxic tumour (Denekamp & Harris,
1975; Denekamp et al., 1980a).
To ensure that an arbitrary choice of
endpoint size did not bias the estimate of
SER' (Denekamp & Harris, 1975; Begg,
1980), the results were re-analysed using a
range of endpoint sizes corresponding to a
volume increase of 4-9-fold. Although it
was found that tumours regrew at rates
which varied with the growth delay
induced by treatment, there was no
significant difference in SER's measured at
different endpoint sizes.
Two comparisons ofthe sensitizers were
made: by administered dose and by
tumour concentration. On the basis of
equimolar dose, no difference was seen
betweenthe 5compounds (Fig. 5). Pharma-
cokinetic differences mean that the basic
compounds achieve lower tumour concen-
trations than MISO after equimolar
dosage (Figs 3 & 4, Table III), and radio-
sensitizing efficiency was therefore
compared on the basis of tumour concen-
tration. Fig. 6 shows that the basic
compounds were up to 4 times as potent as
MISO. This is close to the prediction of a
factor of 3 based on the physicochemical
parameter electron-affinity, but is much
less than the 10-fold increase in potency
seen with V79 cells in vitro (Smithen et al.,
1980), a discrepancy which is explained
below. At low concentrations, equivalent
to those achieved clinically with MISO,
the SER' would only increase from 1-2 to
1P3; such a small difference would not
be detectable in these experiments.
The accuracy of measurements of both
drug concentration in tumours and the
observed SER' determines the reliability
of estimates of relative efficiency of the 5
compounds. The large error bars in Fig. 3
show that the HPLC estimate of Ro 03-
8799 concentration in individual tumours
was more variable than for the other
compounds. Because of this, and because
of the clinical interest in Ro 03-8799, a
complete repeat of this pharmacology
experiment was performed; blood and
tumour concentrations raised up to 2-fold.
The reason for this greater variability
with Ro 03-8799 is not understood, but the
conclusions remain unchanged whichever
set of data is used. The estimates of SER'NEW SENSITIZERS IN VIVO
did not differ significantly in a repeat
experiment (Figs 5 & 6) and the errors were
certainly small enough to have detected
the 10-fold difference in potency predicted
from the in vitro data.
The discrepancy between the in vivo and
in vitro results can be explained, because
the concentration ofa compound at its site
of action is affected by its physico-
chemical and pharmacological properties.
Both the in vitro data in Fig. 1 and the
tumour data in Fig. 6 are expressed in
terms of the gross concentration of drug,
either in the medium surrounding the cells
or in the homogenate made from tumours.
Whilst these seem reasonable estimates,
neither is a direct measure of intracellular
drug concentration. Because charged
molecules cross membranes relatively
poorly (La Du et al., 1971) the distribution
ofbasic compounds is pH-dependent. This
principle of ion trapping was one reason
these compound were thought to have
clinical potential (Wardman, 1982), both
because they should be poorly reabsorbed
from an acid urine, and because they
might accumulate in the acidic regions
shown to exist in tumours (Vaupel et al.,
1981). The 3 charged compounds have
short half-lives as predicted, but the
influence of pH on efficiency depends on
whether the critical hypoxic cells them-
selves are internally acidic or whether
there is simply a fall in extracellular pH. If
there were concentration within hypoxic
acidic cells in tumours, the basic com-
pounds would be expected to be even more
efficient in tumours than in vitro, which
they clearly are not. Conversely, these
drugs would accumulate extracellularly if
the interstitial fluid were acidic but, unless
such regions are a very lare proportion of
the tumour, gross concentrations would
closely parallel those in the critical
hypoxic cells.
A pH-dependent change in the sensi-
tizing efficiency of Ro 03-8799 in vitro has
been reported for hypoxic V79 cells (Watts
& Jones, 1981). The SER for 0*1 mm fell
from 1-54 to 1-33 when the extracellular
pH was reduced from 7-4 to 6-5. Recent
measurements of intracellular concentra-
tions of Ro 03-8799 as a function of
extracellular pH have shown that this
change in SER can be explained by
changes in intracellular drug levels (Clarke
et al., 1982). Somewhat surprisingly, the
concentration of Ro 03-8799 at pH 7*4 (at
25°C) was found to be twice that in the
surrounding medium. With MISO, the
intracellular concentration was only 5000
of that in the medium. This differential
concentration in vitro explains most, ifnot
all, of the unexpectedly high efficiency of
these basic compounds. Thus radiosensi-
tizing efficiency measured in vivo agrees
closely with that measured in vitro, when
the basis of comparison is the intracellular
concentration of each compound. The in
vitro data, expressed in terms of the
concentration in medium, were over-
optimistic, and the 3-fold increase in
efficiency predicted for these 3 basic
compounds from electron-affinity fits both
the corrected in vitro data and the present
tumour results. This intracellular concen-
tration of Ro 03-8799 at physiological pH
would also explain the fact that the
charged compounds achieved higher tum-
our:blood ratios than MISO at 20-30 min
(Fig. 4, Table III). This concentration
effect correlates with pKa (Table I) and
was also observed in other tissues with Ro
03-8799.
The improvement in radiosensitizing
efficiency which we have observed in vivo
with the basic compounds is slight, and
any substantial clinical advantage would
depend on reduced toxicity in man (i.e. the
ability to administer a total of > 12 g/m2
during a course of radiotherapy). Our
toxicity data are limited to acute lethality
and sensitizer concentrations in mouse
brains. Table III shows that Ro 03-8799 is
more toxic than MISO in mice, when
judged bylethality, but less toxic ifjudged
by the AUC for brain; Ro 05-9963 is the
least toxic of all and Ro 31-0052 is the
least toxic of the 3 basic compounds.
However, this assessment bears no direct
relationship to the presumptive limiting
toxicity in man: peripheral neurotoxicity.
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Brown & Workman (1980) have suggested
that neurotoxicity might be reduced by
lowering the lipophilicity ofcompounds by
structural modification, in order to reduce
drug entry into nervous tissue. As they
predict, brain exposure (assessed on the
basis of AUC) is correlated with distribu-
tion coefficient (Tables I & III) and Ro 31-
0052 has the lowest value. This may well
relate to central neuropathy, but does not
seem to predict for clinical peripheral
neuropathy, for the following reason:
although the AUC value for Ro 05-9963
is one fifth that for MISO in the mouse
(Table III), we know that these 2 drugs are
equally toxic for peripheral neuropathy in
man (Dische et al., 1981; Coleman et al.,
1982). Unfortunately, no laboratory assay
in rodents has correctly ranked MISO, Ro
05-9963 and metronidazole, the neurotoxic
dose limits of which have all been estab-
lished in man (Hirst et al., 1979; Clarke et
al., 1980; Conroy et al., 1980; Brown et al.,
1981). The selection of compounds for
extensive animal toxicology before clinical
trial therefore remains arbitrary.
The toxicity of Ro 03-8799 has been
comprehensively examined in rats and
monkeys, with daily i.v. injections over 4
weeks (M. R. Jackson, personal com-
munication). The results with Cynomolqus
monkeys, when compared with previous
experience with MISO in this species, show
that considerably larger doses of Ro 03-
8799 are tolerated, the limiting toxicity
being liver damage rather than neuro-
toxicity. This finding has encouraged
Phase I clinical trials to be undertaken
with Ro 03-8799 (Dische et al., 1982).
The overall enhancement seen with
MISO or any potential successor will be
much less in clinical use than in the results
obtained with large single doses of drug
and X-rays in mice. Any reoxygenation
will markedly diminish the gain there
might otherwise be. The use ofsmall X-ray
doses per fraction will further reduce the
observed SER', because oxic cells will
dominate the response unless reoxygena-
tion is very poor (Denekamp et al., 1980b;
Durand & Olive, 1981; Denekamp &
Joiner, 1982). Nevertheless, sensitiza-
tion has been found in human tumours
treated with 9-10 fractions of irradiation
(Urtasun et al., 1977; Ash et al., 1979). The
presence of hypoxic cells in human tum-
ours is now well documented, and their
persistence for at least 10 fractions in some
tumours is indicated.
Before randomized clinical trials of a
new compound to replace MISO are
initiated, a marked gain in sensitization
needs to be demonstrated in vivo. The
present results are conisistent with a 3-4-
fold increase in potency of the basic
compounds relative to MISO, but at low,
clinically relevant, concentrations, the
improvement in SER' one would then
expect is very small, and will be less still if
the pharmacokinetics in mouse and man
are similar (i.e. if tumour levels of Ro 03-
8799 are lower than those after an
equimolar dose ofMISO). Any substantial
advantage would depend on reduced
toxicity in man; the primate toxicology
results obtained with Ro 03-8799 are
encouraging in this respect.
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